# Boyun Pharmaceutical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/boyun-pharmaceutical

- Industry: Biotechnology
- Headquarters: US
- Total disclosed funding: $130M
- Latest round: Series C (Jan 1, 2022)
- Investors on record: 5

## About

Based in California, US, and founded in 2015, Boyun Pharmaceutical is a biopharmaceutical company that focuses on the development and industrialization of new ophthalmic drugs. In January 2022, Boyun Pharmaceutical raised USD 130 million in a Series C funding led by CDH Baifu Capital, with participation from CCB International, Deyi Capital, Guangdong Investment Limited, PCCW, leaning peaks capital, shut capital, letter silver ambitious health care investment, Xing certificate capital, and hit the East investment. 

Boyun Pharmaceutical offers new ophthalmic drugs for the treatment of ophthalmic diseases like ophthalmic surface, fundus, and glaucoma, which covers 2 indications of international multi-center clinical phase III. 

Boyun Pharmaceutical plans to use its proceeds from a Series C funding for multiple product pipeline clinical trials, registration and commercialization preparations, GMP pilot plant construction, improvement of its production capacity to international standards, and team expansion.

## Funding rounds

- Series C, Jan 1, 2022, $130M — PCCW, CCB International, Deyi Capital, CDH Baifu Capital, Guangdong Investment Limited

## Investors

- PCCW — Series C
- CCB International (https://capitalatlas.ai/funds/ccb-international) — Series C
- Deyi Capital (https://capitalatlas.ai/funds/deyi-capital) — Series C
- CDH Baifu Capital (https://capitalatlas.ai/funds/cdh-baifu-capital) — Series C
- Guangdong Investment Limited — Series C